Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full...(between $1.64 and $1.72 based on approxi...)

fully diluted shares outstanding for the year and a tax rate of 35%.

Recent Events

-- PROCLEIX ULTRIO Post-Marketing Study. Gen-Probe believes the Company

has met its goal of identifying a second case of hepatitis B "yield"

in the post-marketing study for the PROCLEIX ULTRIO assay. Yield is

defined as an HBV-infected blood donation that was intercepted by the

PROCLEIX ULTRIO assay, but that was initially negative based on

traditional serology tests. To date, participating blood banks have

screened approximately 500,000 blood donations in the study. The FDA

has approved the PROCLEIX ULTRIO assay to screen donated blood for

HIV-1 and hepatitis C virus (HCV), but not to screen for HBV, as the

initial clinical studies were not designed to, and did not,

demonstrate HBV yield. Within a month, Gen-Probe intends to submit a

supplemental Biologics License Application (BLA) to the US Food and

Drug Administration in hopes of gaining a donor screening claim for

HBV.

-- Carl Hull Named President and COO. On February 11, Gen-Probe

announced that Carl Hull was named the Company's president and chief

operating officer, effective March 1, 2008. Mr. Hull joined Gen-Probe

in February of 2007 as executive vice president and chief operating

officer. He oversees the Company's major operating functions,

including research and development, manufacturing, and sales and

marketing.

-- New Operations Executive. On November 19, Gen-Probe announced that

Jorgine Ellerbrock joined the Company as senior vice president,

operations. She joined the Company from Invitrogen Corporation, where

she had been vice president, operations, since 2004, most recently for

the Molecul
'/>"/>